- Home
- ENOV vs HRMY Comparison
ENOV vs HRMY Comparison
Compare ENOV & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENOV
- HRMY
- Stock Information
- Founded
- ENOV 1995
- HRMY 2017
- Country
- ENOV United States
- HRMY United States
- Employees
- ENOV N/A
- HRMY N/A
- Industry
- ENOV Fluid Controls
- HRMY Biotechnology: Pharmaceutical Preparations
- Sector
- ENOV Industrials
- HRMY Health Care
- Exchange
- ENOV Nasdaq
- HRMY Nasdaq
- Market Cap
- ENOV 2.2B
- HRMY 2.1B
- IPO Year
- ENOV 2008
- HRMY 2020
- Fundamental
- Price
- ENOV $46.36
- HRMY $33.22
- Analyst Decision
- ENOV Strong Buy
- HRMY Buy
- Analyst Count
- ENOV 10
- HRMY 9
- Target Price
- ENOV $67.44
- HRMY $47.00
- AVG Volume (30 Days)
- ENOV 764.9K
- HRMY 1.3M
- Earning Date
- ENOV 11-06-2024
- HRMY 10-29-2024
- Dividend Yield
- ENOV N/A
- HRMY N/A
- EPS Growth
- ENOV N/A
- HRMY N/A
- EPS
- ENOV N/A
- HRMY 2.11
- Revenue
- ENOV $2,001,668,000.00
- HRMY $681,879,000.00
- Revenue This Year
- ENOV $25.64
- HRMY $24.63
- Revenue Next Year
- ENOV $6.43
- HRMY $18.04
- P/E Ratio
- ENOV N/A
- HRMY $15.77
- Revenue Growth
- ENOV 20.52
- HRMY 25.83
- 52 Week Low
- ENOV $38.27
- HRMY $26.03
- 52 Week High
- ENOV $65.03
- HRMY $41.61
- Technical
- Relative Strength Index (RSI)
- ENOV 61.56
- HRMY 44.15
- Support Level
- ENOV $45.27
- HRMY $32.37
- Resistance Level
- ENOV $47.89
- HRMY $36.68
- Average True Range (ATR)
- ENOV 1.63
- HRMY 2.02
- MACD
- ENOV 0.36
- HRMY -0.07
- Stochastic Oscillator
- ENOV 64.52
- HRMY 20.73
About ENOV Enovis Corporation
Enovis Corp is a medical technology company focused on developing clinically differentiated solutions that generate measurable patient outcomes and transform workflows by manufacturing and distributing high-quality medical devices with a broad use for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company conducts its operations through two operating segments: Prevention & Recovery (P&R) and Reconstructive (Recon). It generates the majority of revenue from the Prevention & Recovery segment.
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant), is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and used for the treatment of cataplexy in adult patients with narcolepsy.